Diana Marcantonio

Diana Marcantonio

Company: Applied BioMath

Job title: Senior Principal Scientist


Application of a quantitative systems pharmacology model to support differentiation of ASP2453, a novel KRASG12C inhibitor 1:00 pm

KRASG12C mutations lead to constitutive proliferation signaling and are prevalent across human cancers. Sotorasib, a KRASG12C inhibitor, was recently approved for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer, and several other KRASG12C inhibitors are in clinical trials.  ASP2453 is a novel, highly-potent, and selective inhibitor of KRASG12C. Will ASP2453 show a more…Read more

day: Day One Track B

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.